Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. Its products include Pemetrexed, WAV-102, and PARP-1 Inhibitors. The company was founded in 2014 and is headquartered in Winnipeg, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Revenue streams and regions a business earns money from
Dividend yield, history and sustainability
Financial position and solvency of the company